报价延迟最少15分钟:2025/09/16 23:15 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
27.23 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.49/0.79
|
|
企业价值
7.48B
|
| 资产负债 |
|
每股账面净值
5.99
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
1.10B
|
|
每股收益
4.10
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/16 23:15 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa. |
